April 5, 2018April 5, 2018

Telo-HL Scoring Model Developed to Predict Relapse Risk in Hodgkin’s Patients, 3DS Says

News

3D Signatures’ Telo-HL test may be one step closer to clinical use with the development of a scoring model designed to predict the risk of relapse in Hodgkin’s lymphoma patients. The company ... Read more

February 21, 2018February 21, 2018

New Technology Identifies Hodgkin’s Patients Unlikely to Respond to Chemotherapy, Company Says

News

A new technology called Telo-HL, developed by 3D Signatures (3DS), is able to distinguish Hodgkin’s lymphoma patients who respond to standard chemotherapy from those who do not, the company announced. An independent analysis ... Read more